CPH · STRAP.CO
Strategic Partners A/S
DKK 635.00DKK 0.00 (0.0%)
Strategic Partners A/S’s quoted price sits in the lower half of its reported 52-week range, 32.88% below the high.
Loading market information…
OTC · RCAR · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
RenovaCare, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow RenovaCare, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
DKK 635.00DKK 0.00 (0.0%)
Strategic Partners A/S’s quoted price sits in the lower half of its reported 52-week range, 32.88% below the high.
$0.00$0.00 (0.0%)
Scopus BioPharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.0% below the high.
$0.00$0.00 (0.0%)
Regenicin, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.99% below the high.
$0.00$0.00 (0.0%)
VioQuest Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00-$0.00 (0.0%)
Q BioMed Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.6% below the high.
$0.00$0.00 (0.0%)
Medite Cancer Diagnostics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
NovAccess Global Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.8% below the high.
$0.00$0.00 (0.0%)
American Scientific Resources, Incorporated’s quoted price sits in the lower half of its reported 52-week range, 70.0% below the high.
